Development of a biomarker of fibromyalgia on neuroinflammation. - Development of a biomarker of fibromyalgia on neuroinflammation.

Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University0 sites80 target enrollmentSeptember 12, 2022

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University
Enrollment: 80
Status: Recruiting
Last Updated: last year

No summary available.

Registry

who.int

Start Date

September 12, 2022

End Date

February 28, 2027

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University

•\[Fibromyalgia] (1\) Patients with symptoms of anemia (hemoglobin 8 g/dl or less) (2\) Patients with poor general condition (PS value \>3\) (3\) Patients diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement\-related disease (PNH, NMO, MS), malignant disease (4\) Other patients deemed by the investigator to be inappropriate as research subjects. \[Chronic pain] (1\) Patients with symptoms of anemia (hemoglobin of 8 g/dl or less) (2\) Patients with poor general condition (numerical value: PS value 3 or higher) (3\) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement\-related disease (PNH, NMO, MS), or malignant disease (4\) Other subjects deemed by the investigator to be inappropriate as research subjects. \[Healthy control] (1\) Those with symptoms of anemia (hemoglobin 8 g/dl or less) (2\) Patients with poor general condition (PS value of 3 or higher) (3\) Patients receiving treatment for pain (4\) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement\-related disease (PNH, NMO, MS), or malignant disease (5\) Any other person whom the investigator deems inappropriate as a research subject.